申请人:Pharma Mar, S.A.U.
公开号:EP2138496A1
公开(公告)日:2009-12-30
New lamellarins are provided of the general formula III :
wherein X is selected from the group consisting of N, O and S;
wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described in the claims and the dotted line represents a single or double bond;
or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.
提供了通式 III 的新型片层蛋白:
其中 X 选自 N、O 和 S 组成的组;
其中 R1、R2、R3、R4、R5、R6、R7、R8 和 R9 如权利要求所述,虚线代表单键或双键;
或其药学上可接受的盐、衍生物、原药或立体异构体。